TargetMol

PX-478

Product Code:
 
TAR-T6961
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T6961-2mg2mg£109.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6961-1mL1 mL * 10 mM (in DMSO)£136.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6961-5mg5mg£136.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6961-10mg10mg£182.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6961-25mg25mg£243.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6961-50mg50mg£304.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6961-100mg100mg£438.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
PX-478 2HCl is an orally active, and selective inhibitor of hypoxia-inducible factor-1α (HIF-1α).
CAS:
685898-44-6
Formula:
C13H20Cl4N2O3
Molecular Weight:
394.11
Pathway:
Chromatin/Epigenetic; Autophagy; Metabolism; Angiogenesis
Purity:
0.9793
SMILES:
Cl.Cl.N[C@@H](Cc1ccc(cc1)[N+]([O-])(CCCl)CCCl)C(O)=O
Target:
HIF/HIF Prolyl-Hydroxylase; HIF; Autophagy

References

Sun K, et al. Mol Cell Biol. 2013, (5), 904-917. Koh MY, et al. Mol Cancer Ther. 2008, 7(1), 90-100. Palayoor ST, et al. Int J Cancer. 2008, 123(10), 2430-2437. Welsh S, et al. Mol Cancer Ther. 2004, 3(3), 233-244. Chang L L, Lu P H, Yang W, et al. AKR1C1 promotes non-small cell lung cancer proliferation via crosstalk between HIF-1? and metabolic reprogramming. Translational Oncology. 2022, 20: 101421 Liu R, Tian Y, Wang J, et al.Visible light?initiated radical 1,3-difunctionalization of ?, ?-unsaturated ketones.Science Advances.2022, 8(49): eabq8596.